883,081 Shares in Medtronic PLC $MDT Purchased by Congress Asset Management Co.

Congress Asset Management Co. purchased a new position in shares of Medtronic PLC (NYSE:MDT) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 883,081 shares of the medical technology company’s stock, valued at approximately $76,201,000. Congress Asset Management Co. owned about 0.07% of Medtronic at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of MDT. Moody National Bank Trust Division increased its stake in shares of Medtronic by 15.5% during the third quarter. Moody National Bank Trust Division now owns 12,611 shares of the medical technology company’s stock worth $1,088,000 after acquiring an additional 1,692 shares during the period. Rosenberg Matthew Hamilton lifted its position in Medtronic by 65.9% in the third quarter. Rosenberg Matthew Hamilton now owns 695 shares of the medical technology company’s stock valued at $60,000 after purchasing an additional 276 shares during the period. Adelphi Trust Co lifted its position in Medtronic by 5.6% in the third quarter. Adelphi Trust Co now owns 3,245 shares of the medical technology company’s stock valued at $280,000 after purchasing an additional 173 shares during the period. Eastern Bank boosted its holdings in Medtronic by 2.9% in the 3rd quarter. Eastern Bank now owns 21,610 shares of the medical technology company’s stock valued at $1,865,000 after purchasing an additional 613 shares in the last quarter. Finally, Rockland Trust Co. boosted its holdings in Medtronic by 10.2% in the 3rd quarter. Rockland Trust Co. now owns 10,113 shares of the medical technology company’s stock valued at $873,000 after purchasing an additional 936 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on MDT shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $92.00 target price on shares of Medtronic in a research note on Thursday, September 3rd. Weiss Ratings raised Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, September 4th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $118.00 price objective on shares of Medtronic in a research report on Wednesday, September 2nd. Stifel Nicolaus raised their target price on Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a report on Wednesday, September 2nd. Finally, Barclays began coverage on shares of Medtronic in a research report on Tuesday. They set a “positive” rating and a $95.00 target price on the stock. Nineteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $102.92.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. The trade was a 3.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic released its fiscal 2026 “Precision with Purpose” Impact Report, highlighting more than 82 million patients served worldwide and progress toward its impact goals. While not a direct earnings catalyst, the report reinforces the company’s global scale and long-term healthcare impact. Medtronic Impact Report Highlights More Than 82 Million Patients Served Worldwide in Fiscal Year 2026
• Positive Sentiment: The American Medical Association granted permanent Category I CPT codes to Medtronic’s Altaviva tibial neuromodulation implant and Symplicity Spyral renal denervation system. Permanent reimbursement codes could improve physician adoption and commercial prospects for these products. Is Medtronic Undervalued Following Its Permanent CPT Code Win?
• Neutral Sentiment: Recent commentary describes MDT as a stable blue-chip dividend stock, with valuation and yield becoming more attractive after its 2026 decline. These are investor opinions rather than new company guidance or operating results. Better Dividend Play for Retirees: MDT or ABT?
• Neutral Sentiment: Analyst-oriented coverage notes that Medtronic recently exceeded quarterly earnings and revenue expectations, supporting the view that the company’s operating performance remains solid. However, no fresh earnings release or updated guidance was provided in these articles.
• Negative Sentiment: The CPT-code coverage notes that MDT remains below its recent highs, with weaker 30-day and year-to-date performance. That lingering underperformance may be keeping investors cautious even after the regulatory reimbursement win. Medtronic Share Performance Following Its CPT Code Win

Medtronic Price Performance

Shares of NYSE:MDT traded down $0.96 during trading on Tuesday, hitting $87.00. 52,133,676 shares of the stock were exchanged, compared to its average volume of 9,832,688. The company has a market cap of $111.29 billion, a PE ratio of 21.43, a P/E/G ratio of 1.97 and a beta of 0.55. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average price of $90.22 and a two-hundred day moving average price of $84.76. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.Medtronic’s quarterly revenue was up 13.7% on a year-over-year basis. During the same period last year, the business posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts forecast that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.